In the next edition of the series, we spoke with Josh Mandel-Brehm, Chief Executive Officer of CAMP4 Therapeutics.
With a wealth of experience in the industry from roles in biotech, investment and pharma, Josh shares his insights into the excitement building around undruggability and how companies are adapting to form successful partnerships and collaborations.
Topics covered include:
Why is the “undruggable” industry so exciting right now, and what other areas of undruggability are you most excited about?
What is the major limiting factor when targeting transcription and how are you working to overcome this?
What lessons are we learning from the partnerships being made for targeting the “undruggable”?